Gene expression relationship between prostate cancer cells of Gleason 3, 4 and normal epithelial cells as revealed by cell type-specific transcriptomes

BMC Cancer

Volumn 9, Issue , 2009, Pages

  Pascal, Laura E ^a,b,e   Vêncio, Ricardo Z N ^c,d   Page, Laura S ^a,b   Liebeskind, Emily S ^a   Shadle, Christina P ^a   Troisch, Pamela ^c   Marzolf, Bruz ^c   True, Lawrence D ^b   Hood, Leroy E ^c   Liu, Alvin Y ^a,b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c INSTITUTE FOR SYSTEMS BIOLOGY   (United States)

^d UNIVERSITY OF SÃO PAULO   (Brazil)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; TRANSCRIPTOME; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CELL ISOLATION; CELL SPECIFICITY; CONTROLLED STUDY; DISEASE MARKER; ENDOTHELIUM CELL; EPITHELIUM BASAL CELL; GENE EXPRESSION; GLEASON SCORE; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; PROSTATE CANCER; PROSTATE EPITHELIUM; STROMA CELL; TRANSCRIPTOMICS; ANTIBODY SPECIFICITY; CANCER STAGING; CARCINOMA; DNA MICROARRAY; EPITHELIUM CELL; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; METABOLISM; PATHOLOGY; PROSTATE TUMOR; TUMOR CELL LINE;

CARCINOMA; CELL LINE, TUMOR; EPITHELIAL CELLS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LYMPHATIC METASTASIS; MALE; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGAN SPECIFICITY; PROSTATIC NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 74549186394     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-9-452     Document Type: Article

References (46)

1. True L, Coleman I, Hawley S, Huang CY, Gifford D, Coleman R, Beer TM, Gelmann E, Datta M, Mostaghel E, Knudsen B, Lange P, Vessella R, Lin D, Hood L, Nelson PS. A molecular correlate to the Gleason grading system for prostate adenocarcinoma. Proc Natl Acad Sci USA 2006, 103(29):10991-10996. 10.1073/pnas.0603678103, 1544162, 16829574.
2. Glinsky GV, Glinskii AB, Stephenson AJ, Hoffman RM, Gerald WL. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004, 113(6):913-923. 362118, 15067324.
3. Reis EM, Nakaya HI, Louro R, Canavez FC, Flatschart T, Almeida GT, Egidio CM, Paquola AC, Machado AA, Festa F, Yamamoto D, Alvarenga R, da Silva CC, Brito GC, Simon SD, Moreira-Filho CA, Leite KR, Camara-Lopes LH, Campos FS, Gimba E, Vignal GM, El-Dorry H, Sogayar MC, Barcinski MA, da Silva AM, Verjovski-Almeida S. Antisense intronic non-coding RNA levels correlate to the degree of tumor differentiation in prostate cancer. Oncogene 2004, 23(39):6684-6692. 10.1038/sj.onc.1207880, 15221013.
4. Bettuzzi S, Scaltriti M, Caporali A, Brausi M, D'Arca D, Astancolle S, Davalli P, Corti A. Successful prediction of prostate cancer recurrence by gene profiling in combination with clinical data: a 5-year follow-up study. Cancer Res 2003, 63(13):3469-3472.
5. Febbo PG, Sellers WR. Use of expression analysis to predict outcome after radical prostatectomy. J Urol 2003, 170(6 Pt 2):S11-19. 10.1097/01.ju.0000095567.03807.a1, 14610405.
6. Singh D, Febbo PG, Ross K, Jackson DG, Manola J, Ladd C, Tamayo P, Renshaw AA, D'Amico AV, Richie JP, Lander ES, Loda M, Kantoff PW, Golub TR, Sellers WR. Gene expression correlates of clinical prostate cancer behavior. Cancer Cell 2002, 1(2):203-209. 10.1016/S1535-6108(02)00030-2, 12086878.
7. Liu AY, Roudier MP, True LD. Heterogeneity in primary and metastatic prostate cancer as defined by cell surface CD profile. Am J Pathol 2004, 165(5):1543-1556. 1618667, 15509525.
8. Dall'Era MA, True LD, Siegel AF, Porter MP, Sherertz TM, Liu AY. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urol 2007, 7:3. 10.1186/1471-2490-7-3, 1829163, 17335564.
9. Oudes AJ, Campbell DS, Sorensen CM, Walashek LS, True LD, Liu AY. Transcriptomes of human prostate cells. BMC Genomics 2006, 7:92. 10.1186/1471-2164-7-92, 1553448, 16638148.
10. Liu AY. Differential expression of cell surface molecules in prostate cancer cells. Cancer Res 2000, 60(13):3429-3434.
11. Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV, Belldegrun AS. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. Prostate 2003, 55(1):71-80. 10.1002/pros.10202, 12640663.
12. Liu AY, True LD, LaTray L, Nelson PS, Ellis WJ, Vessella RL, Lange PH, Hood L, Engh G. Cell-cell interaction in prostate gene regulation and cytodifferentiation. Proc Natl Acad Sci USA 1997, 94(20):10705-10710. 10.1073/pnas.94.20.10705, 23453, 9380699.
13. Liu AY, Zhang H, Sorensen CM, Diamond DL. Analysis of prostate cancer by proteomics using tissue specimens. J Urol 2005, 173(1):73-78.
14. Pascal LE, Goo YA, Vêncio RZN, Page LS, Chambers AA, Liebeskind ES, Takayama TK, True LD, Liu AY. Gene expression down-regulation in CD90+ prostate tumor-associated stromal cells involves potential organ-specific genes. BMC Cancer 2009, 9(1):317. 10.1186/1471-2407-9-317, 2745432, 19737398.
15. Oudes AJ, Roach JC, Walashek LS, Eichner LJ, True LD, Vessella RL, Liu AY. Application of Affymetrix array and Massively Parallel Signature Sequencing for identification of genes involved in prostate cancer progression. BMC Cancer 2005, 5:86. 10.1186/1471-2407-5-86, 1187880, 16042785.
16. Liu AY, True LD. Characterization of prostate cell types by CD cell surface molecules. Am J Pathol 2002, 160(1):37-43. 1867111, 11786396.
17. Pascal LE, Deutsch EW, Campbell DS, Korb M, True LD, Liu AY. The urologic epithelial stem cell database (UESC) - a web tool for cell type-specific gene expression and immunohistochemistry images of the prostate and bladder. BMC Urol 2007, 7:19. 10.1186/1471-2490-7-19, 2231381, 18072977.
18. Vêncio RZ, Koide T. HTself: self-self based statistical test for low replication microarray studies. DNA Res 2005, 12(3):211-214. 10.1093/dnares/dsi007, 16303752.
19. Irizarry RA, Hobbs B, Collin F, Beazer-Barclay YD, Antonellis KJ, Scherf U, Speed TP. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003, 4(2):249-264. 10.1093/biostatistics/4.2.249, 12925520.
20. Marzolf B, Deutsch EW, Moss P, Campbell D, Johnson MH, Galitski T. SBEAMS-Microarray: database software supporting genomic expression analyses for systems biology. BMC Bioinformatics 2006, 7:286. 10.1186/1471-2105-7-286, 1524999, 16756676.
21. Kanehisa M, Goto S. KEGG: kyoto encyclopedia of genes and genomes. Nucl Acids Res 2000, 28(1):27-30. 10.1093/nar/28.1.27, 102409, 10592173.
22. Okada H, Tsubura A, Okamura A, Senzaki H, Naka Y, Komatz Y, Morii S. Keratin profiles in normal/hyperplastic prostates and prostate carcinoma. Virchows Arch A Pathol Anat Histopathol 1992, 421(2):157-161. 10.1007/BF01607049, 1381129.
23. Chan PS, Chan LW, Xuan JW, Chin JL, Choi HL, Chan FL. In situ hybridization study of PSP94 (prostatic secretory protein of 94 amino acids) expression in human prostates. Prostate 1999, 41(2):99-109. 10.1002/(SICI)1097-0045(19991001)41:2<99::AID-PROS4>3.0.CO;2-C, 10477906.
24. Goo YA, Goodlett DR, Pascal LE, Worthington KD, Vessella RL, True LD, Liu AY. Stromal mesenchyme cell genes of the human prostate and bladder. BMC Urol 2005, 5:17. 10.1186/1471-2490-5-17, 1327674, 16343351.
25. Terry S, Yang X, Chen MW, Vacherot F, Buttyan R. Multifaceted interaction between the androgen and Wnt signaling pathways and the implication for prostate cancer. J Cell Biochem 2006, 99(2):402-410. 10.1002/jcb.20983, 16741972.
26. Pelzer AE, Bektic J, Haag P, Berger AP, Pycha A, Schäfer G, Rogatsch H, Horninger W, Bartsch G, Klocker H. The expression of transcription factor activating transcription factor 3 in the human prostate and its regulation by androgen in prostate cancer. J Urol 2006, 175(4):1517-1522. 10.1016/S0022-5347(05)00651-8, 16516039.
27. Brubaker KD, Vessella RL, Brown LG, Corey E. Prostate cancer expression of runt-domain transcription factor Runx2, a key regulator of osteoblast differentiation and function. Prostate 2003, 56(1):13-22. 10.1002/pros.10233, 12746842.
28. Rostad K, Mannelqvist M, Halvorsen OJ, Øyan AM, Bø TH, Stordrange L, Olsen S, Haukaas SA, Lin B, Hood L, Jonassen I, Akslen LA, Kalland KH. ERG upregulation and related ETS transcription factors in prostate cancer. Int J Oncol 2007, 30(1):19-32.
29. Tomlins SA, Rhodes DR, Perner S, Dhanasekaran SM, Mehra R, Sun XW, Varambally S, Cao X, Tchinda J, Kuefer R, Lee C, Montie JE, Shah RB, Pienta KJ, Rubin MA, Chinnaiyan AM. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005, 310(5748):644-648. 10.1126/science.1117679, 16254181.
30. Cantile M, Kisslinger A, Cindolo L, Schiavo G, D'Antò V, Franco R, Altieri V, Gallo A, Villacci A, Tramontano D, Cillo C. cAMP induced modifications of HOX D gene expression in prostate cells allow the identification of a chromosomal area involved in vivo with neuroendocrine differentiation of human advanced prostate cancers. J Cell Physiol 2005, 205(2):202-210. 10.1002/jcp.20384, 15895411.
31. Adam PJ, Boyd R, Tyson KL, Fletcher GC, Stamps A, Hudson L, Poyser HR, Redpath N, Griffiths M, Steers G, Harris AL, Patel S, Berry J, Loader JA, Townsend RR, Daviet L, Legrain P, Parekh R, Terrett JA. Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem 2003, 278(8):6482-6489. 10.1074/jbc.M210184200, 12477722.
32. Zhang JS, Gong A, Cheville JC, Smith DI, Young CY. AGR2, an androgen-inducible secretory protein overexpressed in prostate cancer. Genes Chromosomes Cancer 2005, 43(3):249-259. 10.1002/gcc.20188, 15834940.
33. Zhang Y, Forootan SS, Liu D, Barraclough R, Foster CS, Rudland PS, Ke Y. Increased expression of anterior gradient-2 is significantly associated with poor survival of prostate cancer patients. Prostate Cancer Prostatic Dis 2007, 10(3):293-300. 10.1038/sj.pcan.4500960, 17457305.
34. Kovalev LI, Shishkin SS, Khasigov PZ, Dzeranov NK, Kazachenko AV, Toropygin I, Mamykina SV. [Identification of AGR2 protein, a novel potential cancer marker, using proteomics technologies]. Prikl Biokhim Mikrobiol 2006, 42(4):480-484.
35. Liu AY, LaTray L, Engh G. Changes in cell surface molecules associated with in vitro culture of prostatic stromal cells. Prostate 2000, 44(4):303-312. 10.1002/1097-0045(20000901)44:4<303::AID-PROS7>3.0.CO;2-J, 10951495.
36. Chen ME, Lin SH, Chung LW, Sikes RA. Isolation and characterization of PAGE-1 and GAGE-7. New genes expressed in the LNCaP prostate cancer progression model that share homology with melanoma-associated antigens. J Biol Chem 1998, 273(28):17618-17625. 10.1074/jbc.273.28.17618, 9651357.
37. Kufer P, Zippelius A, Lutterbüse R, Mecklenburg I, Enzmann T, Montag A, Weckermann D, Passlick B, Prang N, Reichardt P, Dugas M, Köllermann MW, Pantel K, Riethmüller G. Heterogeneous expression of MAGE-A genes in occult disseminated tumor cells: a novel multimarker reverse transcription-polymerase chain reaction for diagnosis of micrometastatic disease. Cancer Res 2002, 62(1):251-261.
38. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Cancer Res 1997, 57(6):1086-1090.
39. Inokuchi J, Lau A, Tyson DR, Ornstein DK. Loss of annexin A1 disrupts normal prostate glandular structure by inducing autocrine IL-6 signaling. Carcinogenesis 2009, 30(7):1082-1088. 10.1093/carcin/bgp078, 19351789.
40. Xiao W, Zhang Q, Jiang F, Pins M, Kozlowski JM, Wang Z. Suppression of prostate tumor growth by U19, a novel testosterone-regulated apoptosis inducer. Cancer Res 2003, 63(15):4698-4704.
41. Bjartell A, Johansson R, Björk T, Gadaleanu V, Lundwall Å, Lilja H, Kjeldsen L, Udby L. Immunohistochemical detection of cysteine-rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland. Prostate 2006, 66(6):591-603. 10.1002/pros.20342, 16388501.
42. Hudson DL, Guy AT, Fry P, O'Hare MJ, Watt FM, Masters JR. Epithelial cell differentiation pathways in the human prostate: identification of intermediate phenotypes by keratin expression. J Histochem Cytochem 2001, 49(2):271-278.
43. Blum DL, Koyama T, M'Koma AE, Iturregui JM, Martinez-Ferrer M, Uwamariya C, Smith JA, Clark PE, Bhowmick NA. Chemokine markers predict biochemical recurrence of prostate cancer following prostatectomy. Clin Cancer Res 2008, 14(23):7790-7797. 10.1158/1078-0432.CCR-08-1716, 19047106.
44. Tomlins SA, Mehra R, Rhodes DR, Cao X, Wang L, Dhanasekaran SM, Kalyana-Sundaram S, Wei JT, Rubin MA, Pienta KJ, Shah RB, Chinnaiyan AM. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007, 39(1):41-51. 10.1038/ng1935, 17173048.
45. Fleischmann A, Schlomm T, Huland H, Köllermann J, Simon P, Mirlacher M, Salomon G, Chun FH, Steuber T, Simon R, Sauter G, Graefen M, Erbersdobler A. Distinct subcellular expression patterns of neutral endopeptidase (CD10) in prostate cancer predict diverging clinical courses in surgically treated patients. Clin Cancer Res 2008, 14(23):7838-7842. 10.1158/1078-0432.CCR-08-1432, 19047112.
46. Paradis V, Eschwège P, Loric S, Dumas F, Ba N, Benoît G, Jardin A, Bedossa P. De novo expression of CD44 in prostate carcinoma is correlated with systemic dissemination of prostate cancer. J Clin Pathol 1998, 51(11):798-802. 10.1136/jcp.51.11.798, 500969, 10193318.